![Chronic lower respiratory diseases / Respiratory therapy / Respiratory diseases / Asthma / Chronic obstructive pulmonary disease / Chronic condition / Sanofi / Bronchial hyperresponsiveness / Obstructive lung disease / Firestone Institute for Respiratory Health Chronic lower respiratory diseases / Respiratory therapy / Respiratory diseases / Asthma / Chronic obstructive pulmonary disease / Chronic condition / Sanofi / Bronchial hyperresponsiveness / Obstructive lung disease / Firestone Institute for Respiratory Health](https://www.pdfsearch.io/img/5e0fca2cffa37272ac826c7620578787.jpg) Date: 2015-07-30 04:30:57Chronic lower respiratory diseases Respiratory therapy Respiratory diseases Asthma Chronic obstructive pulmonary disease Chronic condition Sanofi Bronchial hyperresponsiveness Obstructive lung disease Firestone Institute for Respiratory Health | | ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company in China, announced todayAdd to Reading ListSource URL: www.zailaboratory.comDownload Document from Source Website File Size: 359,53 KBShare Document on Facebook
|